Core Viewpoint - The article highlights the successful B+ round financing of the innovative company "未名拾光" (Unnamed Light), which focuses on bioactive raw materials, emphasizing its growth trajectory and the strategic use of AI in its operations [2][4]. Financing Overview - "未名拾光" has completed multiple financing rounds since its establishment in 2021, with the latest B+ round raising several million RMB, following significant investments from major players like 欧莱雅 (L'Oréal) and 纳爱斯集团 (Nais Group) [2][3]. - The company has raised funds in six rounds, with notable amounts including approximately 500 million RMB in the Pre-A round and nearly 1 billion RMB in the A round [3]. Technology and Innovation - The company has developed an "AI + synthetic bio" platform for material innovation, focusing on applications from daily care to medical uses, enhancing product design and production efficiency [4][5]. - The AI engine leverages tools like AlphaFold to improve R&D efficiency, achieving a fivefold increase in development speed for innovative raw materials [5]. Production Capabilities - "未名拾光" employs a dual-cell factory model, utilizing both microbial and plant cell factories to produce various protein products, including peptides and collagen [6]. - The company has successfully induced callus tissue from over 80 rare plant species, with three extracts already registered as new cosmetic raw materials, showcasing industry-leading technology transfer efficiency [6]. Business Model - The company operates under a "self-research + CRDMO" model, focusing on both independent innovation and collaboration with downstream brands for new raw material development [8]. - The approach includes reverse development based on customer needs, particularly in the extraction of rare plant materials, and the creation of specialized collagen types for targeted applications [8]. Future Outlook - The completion of the B+ round financing marks a significant milestone for "未名拾光," indicating a new phase of technological, market, and production capacity development, which is expected to invigorate the industry [8].

Core Viewpoint - Anhui Huaheng Biotechnology Co., Ltd. has submitted an application for listing on the Hong Kong Stock Exchange, with Huatai International as the sole sponsor [1] Company Overview - Huaheng Biotechnology is a pioneer in synthetic biotechnology, focusing on the research, large-scale production, and commercialization of bio-based products [3] - The company has established a leading position in the industry through two decades of experience in biomanufacturing, with strong R&D capabilities and mature mass production capabilities [3] Market Position - According to Frost & Sullivan, Huaheng is one of the most comprehensive companies in the commercial application of bio-based products through synthetic biotechnology [3] - The company is the first globally to industrialize the anaerobic fermentation of a series of amino acids, including L-Alanine and L-Valine, and holds the largest market share for these products as of 2024 [3] Client Relationships - As of June 30, 2025, the company has established stable long-term partnerships with over 768 clients across 85 countries in major markets including Asia, Europe, and America [4] Product Portfolio - The main bio-based products include amino acids (primarily alanine series, L-Valine, tryptophan, arginine), vitamins (D-Calcium Pantothenate, D-Pantothenol, inositol), and other bio-based products [4] - The products are widely used in various industries such as animal nutrition, personal care, food and beverage, advanced materials, and plant nutrition [4] Manufacturing Technology - The company employs two green manufacturing technology platforms: fermentation and enzyme catalysis, focusing on microbial cell factories and enzyme-based production processes [4] - This technology aims to replace traditional chemical synthesis with renewable biological resources, reducing pollution and energy consumption while minimizing carbon footprints [4] Market Growth - The global bio-based products market is projected to grow from USD 22.8 billion in 2020 to USD 42.1 billion by 2024, with a compound annual growth rate (CAGR) of 16.6% [5] - The market is expected to further increase to USD 80.1 billion by 2030 and USD 109.1 billion by 2035, with a CAGR of 11.3% from 2024 to 2030 and 6.4% from 2030 to 2035 [5] Financial Performance - The company's revenue for the years 2022, 2023, 2024, and the first half of 2025 was approximately RMB 1.419 billion, RMB 1.938 billion, RMB 2.178 billion, and RMB 1.489 billion respectively [5] - The corresponding profits for the same periods were approximately RMB 319 million, RMB 447 million, RMB 185 million, and RMB 109 million [5][6]

Core Viewpoint - Anhui Huaheng Biotechnology Co., Ltd. (Huaheng Bio) has submitted an application for listing on the Hong Kong Stock Exchange, with Huatai International as the sole sponsor [1]. Company Overview - Huaheng Bio is a pioneer in synthetic biology, focusing on the research, large-scale production, and commercialization of bio-based products through biomanufacturing technology. The company has established a leading position in the industry over the past 20 years [3]. - The company is recognized as one of the most comprehensive enterprises in the commercialization of bio-based products through synthetic biology, being the first globally to industrialize the anaerobic fermentation of a series of amino acids, including L-Alanine and L-Valine. By 2024, it is projected to hold the largest market share for L-Alanine and L-Valine globally [3]. Product Portfolio - As of June 30, 2025, Huaheng Bio has established stable long-term partnerships with over 768 customers across 85 countries in Asia, Europe, and the Americas. Its main bio-based products include amino acids (primarily alanine series, L-Valine, tryptophan, arginine), vitamins (D-Calcium Pantothenate, D-Pantothenol, inositol), and other bio-based products (1,3-propanediol, succinic acid, malic acid, arbutin) [4]. - The company employs two green manufacturing technology platforms: fermentation and enzyme catalysis, focusing on microbial cell factories and enzyme-based production processes to reduce pollution, lower energy consumption, and minimize carbon footprints [4]. Market Potential - The global bio-based products market is expected to grow from $22.8 billion in 2020 to $42.1 billion by 2024, with a compound annual growth rate (CAGR) of 16.6%. It is projected to further increase to $80.1 billion by 2030 and $109.1 billion by 2035, with CAGRs of 11.3% and 6.4% respectively [5]. - Companies with green manufacturing capabilities, large-scale production technologies, and collaborative advantages in the supply chain are anticipated to experience unprecedented growth opportunities in this market [5]. Financial Performance - The company reported revenues of approximately RMB 1.419 billion, RMB 1.938 billion, RMB 2.178 billion, and RMB 1.489 billion for the years 2022, 2023, 2024, and the first half of 2025, respectively. The corresponding profits for these periods were approximately RMB 319 million, RMB 447 million, RMB 185 million, and RMB 109 million [5][7].

Core Viewpoint - Anhui Huaheng Biotechnology Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, with Huatai International as the sole sponsor [1]. Company Overview - Huaheng Biotechnology is a pioneer in synthetic biology, focusing on the research, large-scale production, and commercialization of bio-based products through biomanufacturing technology [3]. - The company has established an industry-leading position in research and development, technology innovation, and mass production capabilities over the past twenty years in the biomanufacturing field [3]. - According to Frost & Sullivan, Huaheng is one of the most comprehensive companies globally in commercializing bio-based products through synthetic biology [3]. Product Portfolio - The company's bio-based products include amino acids (mainly L-alanine and L-valine), vitamins (such as D-calcium pantothenate and D-panthenol), and other bio-based products like 1,3-propanediol and succinic acid [4]. - These products are widely used across various industries, including animal nutrition, personal care, food and beverage, advanced materials, and plant nutrition [4]. - Huaheng employs fermentation and enzyme catalysis as its two main green manufacturing technology platforms, focusing on microbial cell factories and enzyme-based production processes [4]. Market Potential - The global bio-based products market is projected to grow from USD 22.8 billion in 2020 to USD 42.1 billion by 2024, with a compound annual growth rate (CAGR) of 16.6% [5]. - The market is expected to further increase to USD 80.1 billion by 2030 and USD 109.1 billion by 2035, with CAGRs of 11.3% from 2024 to 2030 and 6.4% from 2030 to 2035 [5]. - Companies with green manufacturing capabilities, large-scale production technologies, and collaborative advantages in the supply chain are anticipated to experience unprecedented growth opportunities in this context [5]. Financial Performance - The company's revenue for the years 2022, 2023, 2024, and the first half of 2025 was approximately RMB 1.419 billion, RMB 1.938 billion, RMB 2.178 billion, and RMB 1.489 billion, respectively [5]. - The corresponding profits for the same periods were about RMB 319 million, RMB 447 million, RMB 185 million, and RMB 109 million [5]. - The gross profit margins for these years were 38.7%, 40.4%, 24.8%, and 23.5%, respectively, indicating fluctuations in profitability [7].

Core Viewpoint - The company is currently not utilizing synthetic biology technology for the development of water buffalo milk-related products, and is in the research phase regarding the feasibility and cost-effectiveness of using microbial protein raw materials in biological fermentation milk buffalo feed [1] Group 1 - The company has stated that it is monitoring and evaluating the application of synthetic biology technology [1] - The research is focused on the potential use of microbial protein in water buffalo feed [1] - The current status of the project is still in the scientific research phase [1]

Core Viewpoint - The company is currently not applying synthetic biology technology for the development of water buffalo milk-related products, and it is still in the research phase regarding the feasibility and cost-effectiveness of using microbial protein raw materials in biological fermentation for water buffalo feed [1]. Group 1 - The company has received inquiries about expanding synthetic biology technology into dairy product research and production [1]. - The company is evaluating the application of synthetic biology technology in the production of microbial protein for water buffalo feed, but this is still in the scientific research stage [1].

Core Insights - "Weiming Shiguang" recently secured several tens of millions of RMB in B+ round financing, led by Huatai Jinse and Haibang Investment, aimed at enhancing AI technology platform development, expanding diverse applications of biomaterials, and accelerating global business layout [1] - The company has developed a closed-loop synthetic biology technology platform focusing on innovative biomaterials, utilizing AI to empower the platform comprehensively [1][3] - The company has established a business model that meets the needs of the beauty, medical device, and food industries, combining self-developed innovative raw material pipelines with a CRDMO model to collaborate with downstream brand manufacturers [1][6] Investment and Financing - The recent financing follows nearly 100 million RMB investment from L'Oréal and Nai's Group in May, indicating strong investor confidence and interest in the company's growth potential [1] - The funds will primarily be used for AI technology platform enhancement and global business expansion [1] Technology and Innovation - The company has established two types of cell factories—microbial and plant-based—to produce peptides and proteins, including collagen and fibronectin [2] - Utilizing plant callus technology, the company has induced callus from over 80 plant species, with three extracts approved as new cosmetic raw materials, representing 75% of the total approved by the regulatory authority [2] - AI has significantly improved research and development efficiency, reportedly increasing it by at least five times, with plans to allocate 50% of R&D spending towards AI development [4] Product Development and Market Strategy - The company employs a "reverse development" approach, focusing on the needs of downstream brand clients to provide raw material development services [6] - The emphasis is on developing differentiated "high-end" raw materials, particularly rare plant extracts that offer unique market value [6] - The company aims to expand its active ingredient business from beauty products to food and daily chemicals, with plans for international expansion [8] Collaboration and Client Network - The company has established a wide market channel and client network, collaborating with major brands like L'Oréal, Procter & Gamble, and Shanghai Jahwa for joint development [7] - The introduction of a novel "in vivo transdermal absorption Raman spectroscopy detection" technology has attracted numerous beauty and personal care brands, enhancing client relationships and laying the groundwork for CRDMO services [7]

Core Viewpoint - The company "未名拾光" has recently secured a B+ round financing of several tens of millions of RMB, following a previous investment of nearly 100 million RMB from L'Oréal and Naive Group, aimed at enhancing its AI technology platform and expanding its global business footprint [3][4]. Group 1: Financing and Investment - "未名拾光" has received significant investments from both L'Oréal and Naive Group, totaling nearly 100 million RMB earlier this year, and has now attracted additional funding from industrial funds [4]. - The latest financing round will primarily focus on deepening AI technology platform development and expanding the application scenarios of biological materials [3]. Group 2: Technology and Product Development - The company has established a closed-loop system for the innovation of biological materials, integrating design, screening, efficacy evaluation, and large-scale production, empowered by AI [4]. - "未名拾光" is developing two main categories of biological raw materials: plant callus tissues and bioactive proteins, including recombinant collagen and peptides [4]. - The company has created a dual-cell factory system utilizing both microbial and plant cell factories to produce various products, including rare plant active molecules [6]. Group 3: AI Integration - The team recognized the value of AI early in the development of their synthetic biology technology platform, utilizing tools like AlphaFold and RFDiffusion to enhance research efficiency [7]. - AI has significantly improved research efficiency, reportedly increasing it by at least five times, with plans to allocate 50% of R&D spending towards AI development [8]. Group 4: Business Model and Market Strategy - "未名拾光" employs a CRDMO model (CRO + CDMO) to collaborate with downstream brand partners for the development of new biological raw materials and provide contract manufacturing services [4][10]. - The company has successfully validated its model in the plant metabolite category, expanding its client base to include numerous well-known domestic and international brands [11]. Group 5: Future Directions - The company plans to expand its business in bioactive raw materials from the beauty sector to food and daily chemical applications, while also seeking international market opportunities [13].

"长三角聚劲科创大赛"是面向全球科技型创新创业项目的顶尖专业赛事，旨在发现、挑选和培育一批具 备技术领先性和商业化潜力的科技创业翘楚。"长三角聚劲科创大赛"自2022年升级以来，复旦大学管理 学院以赋能科创企业为初心，将管理认知赋能、投融资源链接嵌入每一场赛事。最终，成长组"合成生 物技术驱动二氧化碳固定和高值化利用"项目荣获聚劲大奖，天使组"ORCA物理AI仿真系统"项目与"应 用于新型显示的量子点光转换器件"项目荣获天使组一等奖。 复旦大学管理学院院长陆雄文表示，2025赛季，我们广邀全球优秀的科创项目参赛，更加聚焦"早、 小、硬"项目成长，为"天使组"初创项目提供更多资源支持。今年的参赛项目主要有三个特征：一是更 年轻，印证了中国科创的接力棒正逐步交到年轻一代手中的重要趋势。二是更国际化，一方面本赛季拥 有国际院校学历背景的创始人占比近40%，相较前两赛季实现了跨越式增长；另一方面表现在项目的出 海属性上，众多项目从诞生之初就锚定海外市场，以国际需求为创业起点。三是更多AI驱动，与往届 相比，AI项目明显增多。人工智能已从特定工具演变为普遍性赋能要素，深刻融入各赛道创新内核。 9月20日，"长三角聚劲科 ...

Group 1: Company Operations and Market Position - The company is the largest producer of Coenzyme Q10 globally, recognized for its quality and production capacity, which is at the industry's leading level [2][3] - The company has undergone capacity expansion and transformation, significantly reducing production costs and increasing market share, thereby reinforcing its dominant market position [3] - Coenzyme Q10 is widely used in cardiovascular health and anti-aging sectors, with market demand expected to continue growing due to global aging and rising health awareness [3] Group 2: Product Development and Market Strategy - The company plans to closely monitor developments in the health and biosynthesis sectors, aligning R&D projects with market prospects and enhancing its synthetic biology research platform [2] - The company aims to strengthen its raw material supply chain and accelerate the industrialization of new products, focusing on biosynthesis research and global brand strategy [3] - The company is committed to building a strong brand presence in the health supplement market through a "big product + product matrix" strategy, leveraging both raw material and brand advantages [3] Group 3: Competitive Landscape - The U.S. dietary supplement market is highly fragmented, with the company focusing on maintaining its operational philosophy and differentiation to enhance market share for its star products [3] - The Doctor's Best brand emphasizes the use of high-quality raw materials and targets consumers interested in scientifically formulated nutrition, maintaining a leading position in the market [3]